Abstract
Resistance to cis- or carboplatin represents the principal cause of therapeutic failures in ovarian carcinoma. The phenomenon of resistance to platinum-based drugs is partly related to expression of metallothionein (MT) and of glutathione S-transferase pi (GST-pi), but opinion on the subject is discordant. Documentation of a negative predictive effect of MT and GST-pi expression for the therapy employing platinum-based drugs would permit to select resistant cases in which other therapeutic approaches could be employed. The present study aimed at examining the relation between intensities of MT and GST-pi expressions in ovarian carcinomas and dynamics of the clinical course in the neoplastic disease in a group of cisplatin-treated patients. The analyses were performed on samples of ovarian carcinoma originating from 43 first-look laparotomies (FLLs) and, in 30 cases, from second-look laparotomies (SLL) from the same patients. Immunohistochemical reactions were performed on paraffin sections of studied tumors, using monoclonal antibodies to MT and GST-pi. The calculations showed that in cases with augmented expression of MT, mortality was higher. On the other hand, augmented expression of GST-pi predisposed to more frequent relapses, deaths and progression of the tumor. Kaplan–Meier analysis showed that a significantly shorter survival time was linked to cases of higher expression of MT at FLL and of higher expression of GST-pi at FLL, whereas a shorter progression-free time was manifested by cases with higher expression of GST-pi at FLL. The performed investigations indicate that augmented expressions of MT at FLL and GST-pi at FLL in ovarian cancer represent an unfavourable predictive factor in cisplatin-treated patients.
Similar content being viewed by others
References
Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa HC, Chmiel JS, Zuber K, Karnel LH, Winchester DPSO (1993) National survey of ovarian carcinoma. 1. A patient care evaluation study of the American College of Surgeons. Cancer 71:1629–1638
Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD (2003) Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63:8097–8102
Dzięgiel P, Forgacz J, Suder E, Surowiak P, Kornafel J, Zabel M (2003) Prognostic significance of metallothionein expression in correlation with Ki67 expression in adenocarcinomas of large intestine. Histol Histopathol 18:401–407
Goto S, Kamada K, Soh Y, Ihara Y, Kondo T (2002) Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res 93:1047–1056
Hagrman D, Goodisman J, Dabrowiak JC, Souid AK (2003) Kinetic study on the relation of cisplatin with metallothionein. Drug Metab Dispos 31:916–923
Hamer DH (1986) Metallothionein. Annu Rev Biochem 55:913–951
Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Igarashi M, Tachibana M, Nagasue N (1997) Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Lab Invest 54:342–347
Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M, Nagasue N (1999) Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer 81:712–720
Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Sem Surg Oncol 19:3–10
Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H, Shimizus M, Minanami H, Sakuragi N (2003) Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II–IV ovarian cancer. Int J Gynecol Cancer 13:776–784
Kagi JHR (1991) Overview of metallothionein. Methods Enzymol 205:613–626
Kaina B, Lohrer H, Karin M, Herrlich P (1990) Overexpressed human metallothionein IIA gene protects Chinese hamster ovary from killing by alkylating agents. Proc Natl Acad Sci U S A 87:2710–2714
Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478:23–43
Konishi I, Nanbu K, Mandai M, Tsuruta Y, Kataoka N, Nagata Y (1998) Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. Gynecol Oncol 70:365–371
Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijeng LH, Bokemeyer C (2003) Molecular determinants of treatment response in human germ-cell tumors. Clin Cancer Res 9:767–773
Mayr D, Pannekamp U, Baretton GB, Gropp M, Meier W, Flens MJ, Scheper R, Diebold J (2000) Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 196:469–475
McCluggage WG, Strand K, Abdulkair A (2002) Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumours. Int J Gynecol Cancer 12:62–65
Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, Zwart N, Sleijefer DT, Mulder NH (2000) Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85(6):777–781
Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M (2003) Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res 23:2829–2836
Muramatsu Y, Hasegawa Y, Fukano H, Ogawa T, Namuba M, Mour S, Fujimoto Y, Matsuura H, Takai Y, Mori M (2000) Metallothionein immunoreactivity in head and neck carcinomas—special reference to clinical behaviors and chemotherapy responses. Anticancer Res 20:257–264
Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rasmussen AA, Montgomery EA, Bischoff EK, Cullen KJ (1996) Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 2:1859–1865
Remmele W, Stegner HE (1987) Recommendation for uniform definition of an ImmunoReactive Score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140
Satoh T, Nishida M, Tsunoda H, Kubo T (2001) Expression of glutathione S-transferase pi (GST-pi) in human ovarian tumors. Eur J Obstet Gynecol Reprod Biol 96:202–208
Shimizu Y, Kamoi S, Amada S, Silverberg SG (1998) Toward the development of a universal grading system of ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893–901
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279
Siegsmund MJ, Marx C, Seeman O, Schummer B, Steidler A, Toktomambetova L, Kohrmann KU, Rassweiler J, Alken P (1999) Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol Res 27:157–163
Siu LL, Banerjee D, Khurana RJ, Pan X, Pflueger R, Tannock IF (1998) The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4:559–565
Surowiak P, Dzięgiel P, Matkowski R, Kornafel J, Wojnar A, Zabel M (2002) Immunohistochemical evaluation of metallothionein (MT) expression in myoepithelial cells of ductal mammary carcinoma and its relation to survival time: analysis of 7 year-course of the disease. Folia Histochem Cytobiol 40:105–106
Toyoda H, Mizushima T, Satoh T, Iizuka N, Nomoto A, Chiba H, Mita M, Naganuma A, Himeno S, Imura N (2000) HeLa cell transformants overproducing mouse metallothionein show in vivo resistance to cis-platinum in nude mice. Jpn J Cancer Res 91:91–98
UICC (1997) TNM classification of malignant tumors. In: Sobin LH, Wittekind C (eds). Wiley-Liss, New York
Van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Wilemse PHB, Aalders JG, Vries EGE (1995) Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70–78
Wrigley E, Verpaget HW, Jayson GC, McGown AT (2000) Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 126:717–721
Acknowledgements
The study was supported by the grant no. 3 PO5E 064 22 from the Committee of Scientific Investigations, Poland, and by the “Berliner Krebsgesellschaft e.V.”, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Surowiak, P., Materna, V., Kaplenko, I. et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 447, 626–633 (2005). https://doi.org/10.1007/s00428-005-1228-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-005-1228-0